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Abstract
Introduction. Among patients suffering from atrial fibrillation (AF), there is a certain population with episodes of typical 
atrial flutter (AFL). A detrimental effect of atrial remodelling caused by AF is well known, therefore duration of AF is an 
important prognostic issue for such patients. In our study we attempted an approach consisting of cavotricuspid isthmus 
(CTI) radiofrequency (RF) ablation and aldosterone receptor blocker administration for a purpose of maintaining sinus 
rhythm. The aim of this study was to assess long-term effects of such treatment in patients with AFL and/or AF.
Materials and methods. Population of 64 patients aged 64.7 years was divided into 3 groups: I — AFL (n = 34); II — AFL 
with paroxysmal AF (n = 13); III — persistent AF despite antiarrhythmic treatment (n = 17). CTI ablation was performed 
in all individuals, with subsequent direct current cardioversion in group III. Postablative antiarrhythmic medications were 
started in all patients in group II whilst in group III the current treatment was continued. Aldosterone receptor blocker 
was implemented in a part of group I and in all remaining patients. The mean follow-up period was 13.9 months.
Results. In group I, typical AFL recurrence occured in 3 patients (8.8%). In group II, 1 AFL recurrence was successfully 
treated with repeated ablation, and 1 AF relapse was noted. In group III, 7 AF relapses were treated definitely with 
pulmonary vein isolation or accepted as permanent AF. The primary success rate of the procedure was 91% vs. 85% 
vs. 59 % (p < 0.05).
Conclusions. CTI ablation is a therapeutic procedure for AFL and AFL concomitant with paroxysmal AF. Such procedure 
makes a moderately successful alternative for patients with persistent AF, while treatment with propafenone and aldo-
sterone receptor blocker is provided. CTI ablation may constitute a bridging therapy aimed at preserving sinus rhythm 
in patients awaiting the pulmonary vein isolation.
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Introduction
The coincidence of common atrial flutter (AFL) and atrial 
fibrillation (AF) is well known in clinical practice, however 
the interrelationship between them has not been fully 
understood. The 2016 ESC Guidelines on atrial fibrillation 
recommend to consider ablation of both arrhythmias as 
one therapeutic approach [1]. From a practical point of 
view, it should be emphasized that the experienced cen-
tres and operators have much too many patients waiting 
for the procedures to be performed and during this period 
some arrhythmias are considered to become permanent. 
Moreover, some circumstances may complicate performing 
the treatment and impede reaching a long-term success 
rate. Firstly, the type of AF (paroxysmal, persistent and 
long-standing persistent) affects an acute and long-term 
effect of pulmonary vein isolation (PVI). Recent data from 
a large STAR-AF II study presenting a comparison of three 
methods of persistent AF ablation (PVI alone, PVI plus 
ablation of complex fractionated electrograms or PVI plus 
lines in left atrium) shows 50–60% a success rate in the 
18-month follow-up period [2]. There are several possible 
mechanisms of relatively low effectiveness of ablation in 
such patients. Multiple stressors, such as stretching of 
atrial myocardium, episodes of AF or other supraventricular 
arrhythmias, and renin–angiotensin–aldosterone system 
(RAAS) activation, are responsible for atrial remodelling and 
fibrosis. AF forms in the tissue self-perpetuating process 
facilitating the arrhythmia itself, the progression of elec-
trophysiological and structural remodelling, and depleting 
successful therapeutic options. Despite the initial over-op-
timistic results of large trials pointing out that there is no 
difference in outcomes in the rhythm control group and the 
rate control one [3], in following summaries it was noted 
that restoration of sinus rhythm in an adequate fashion pro-
motes lower mortality and morbidity. The approach presen-
ted in this paper is a modified hybrid therapy mentioned in 
the literature, that consists of radiofrequency (RF) ablation 
of cavotricuspid isthmus and pharmacological treatment.
The aim of this pilot study was to assess the middle-
to-long-term efficacy of CTI ablation in patients with AFL/ 
/AF and AF.
Materials and methods
Sixty-four consecutive patients with typical AFL or AF who 
underwent radiofrequency catheter ablation were qualified 
to this study. Those with alone common-type AFL (n = 34, 
group I) received no anti-arrhythmic drug (AAD) therapy, 
before and after hospitalization. Group II consisted of 13 
patients with AFL who either had concomitant paroxysmal 
AF or who suffered from paroxysmal AF during the ablation 
procedure. Patients with persistent AF despite previous 
appropriate AAD therapy in medical records (n = 17) 
constituted a Group III. AAD, mostly propafenone, were 
administered by referring cardiologists. Group III patients 
were treated with direct current cardioversion during the 
RF ablation procedure with subsequent assessment of 
CTI block and additional energy application if necessary. 
Post-procedural AAD was administered in group II whilst in 
group III the current treatment was continued.
We performed an initial clinical evaluation that included 
past medical history, physical examination, 12-lead surface 
electrocardiogram (ECG), blood chemistry tests and trans-
thoracic echocardiography with colour flow Doppler measu-
rements prior to the procedure in all of the patients. Oral 
anticoagulation was prescribed according to CHA2DS2VASc 
risk score. The use of medications, including beta-adreno-
lytics, AAD, angiotensin-converting enzyme inhibitors, was 
determined at the discretion of the responsible clinician. 
This study was carried out in accordance with the Principles 
of the Declaration of Helsinki (1975) and approved by the 
local Ethical Committee. All enrolled patients gave their 
written informed consent.
Performed RF ablations were aimed at acquiring cavotri-
cuspid isthmus bidirectional block, assessed after 20 minu-
tes of observation. A standard diagnostic quadripolar elec-
trode (Boston Scientific, Boston, MA, USA) was placed in the 
coronary sinus, and afterwards 8 mm ablative catheter (Bard 
Electrophysiology, C.R. Bard, Lowell, MA, USA or Boston 
Scien tific, Boston, MA, USA) or mini electrode-tipped (IntellaTip 
MiFi XP, Boston Scientific, Boston, MA, USA) were located 
under fluoroscopy at CTI area. The standard procedure of 
EPS was performed in patients with AFL prior to ablation. 
CTI-dependence of circulatory wave was proved by entrain-
ment pacing. Bidirectional isthmus block was confirmed by 
pacing from the coronary sinus ostium and the low lateral 
right atrium in the presence of double potentials. Group 
III patients with initial AF were treated with direct current 
cardioversion (DCC) (300–360 J) after initial application 
of RF energy, with further assessment of ablation line and 
additional RF application if needed. After DCC, patients were 
monitored at intensive cardiac care unit. The follow-up was 
performed at outpatient clinic or at referring cardiologists, 
and consisted of taking medical history towards symptoms 
of arrhythmia, echocardiography and ECG-Holter monitoring.
The study protocol was approved by local Bioethics 
Committee — KB-166/2017.
The results were presented as means and standard de-
viations or percentages, as appropriate, and were compared 
using multi-variate analysis (1-way ANOVA). Calculations were 
performed using the STATISTICA v12.0 statistical package, 
where p < 0.05 was considered as statistically significant.
Results
Clinical characteristics of enrolled population are presen-
ted in Table 1. These parameters were perfectly matched 
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for 3 groups (with no statistically significant differences 
among them). Periprocedural parameters were measured, 
including the number of RF applications, total ablation time, 
mean temperature, mean impedance, and mean power 
during the applications. These results were also similar 
among all groups, and listed in Table 2. Arrhythmia-free 
survival among the studied patients was shown using the 
Kaplan-Meier survival curves (Fig. 1).
In group I the AFL recurrence was present in 3 patients 
(8.8%) and was successfully terminated in all 3 patients 
(8, 11 and 14 months). No AF was observed during the 
follow-up. In Group II there was 1 AFL recurrence (after 
5 months) treated successfully with repeated ablation, and 
1 AF episode treated with propafenone with signs of sinus 
node dysfunction and a subsequent pacemaker implanta-
tion (11 months atrial pacing without arrhythmia episodes). 
In group III, 7 AF relapses were treated definitely with 
pulmonary veins isolation or accepted as permanent AF.
Discussion
It has been shown that administration of Class Ic AAD 
can transform AF into AFL. Class Ic AAD causes slowing 
conduction, prolongation of the atrial refractory period 
and decrease excitability of myocardium. Thus, it may 
promote forming larger re-entry loops (flutter wave) rather 
than smaller circuits (fibrillation activity). However, the 
clinical and electrophysiological background underlying the 
organization of AF into AFL during antiarrhythmic therapy 
is not fully proved [4, 5]. Such evolution was reported in 
the early 1990s in up to 20% of patients receiving Ic AAD 
treatment (so-called Ic AAD-AFL) [6]. Hence, providing the 
beta-adrenolytic treatment in order to avoid 1:1 conduction 
was necessary. Some studies were performed on that basis 
[4, 7, 8] and reported that among patients suffering from 
refractory AF, who develop Ic AAD-AFL after a successful 
CTI ablation, AF recurrences were reduced.
Radiofrequency ablation of CTI was constantly consi-
dered as elimination of one of the possible factors driv-
ing AF. The concept was based on hypothesis that in some 
patients AF is facilitated and/or perpetuated by a re-entry 
loop circulating through CTI. This re-entrant activation 
can be conducted to the left atrium by the Bachmann’s 
bundle or the coronary sinus. The most interesting issue is 
its efficacy in populations suffering from AFL concomitant 
with paroxysmal, or even more important, persistent AF. 
Such approach was reported in a few papers. The mean 
follow-up time was different in those studies. Reithmann 
et al. conducted an observation of 46 patients with 
Table 1. Baseline patients’ clinical characteristics
Parameter Group I 
(n = 34)
Group II 
(n = 13)
Group III  
(n = 17)
p value
Women 20 (58.8%) 7 (53.8%) 11 (64.7%) NS
EHRA score 2.3 ± 0.7 2.4 ± 0.7 2.2 ± 0.8 NS
Hypertension 20 (58.8%) 6 (46.1%) 8 (57.1%) NS
CAD 2 (5.9%) 2 (15.4%) 2 (11.8%) NS
Heart failure 1 (3%) 0 1 (7.1%) NS
Diabetes mellitus 10 (29.4%) 2 (15.4%) 2 (14.3%) NS
Stroke 5 (14.7%) 2 (15.4%) 3 (21.4%) NS
Medications:
• beta-adrenolytics 25 (73.5%) 9 (69%) 11 (78.5%) NS
• CCB 5 (14.7%) 1 (7.7%) 1 (7.1%) NS
• ACEI or ARB 13 (38.2%) 3 (23%) 5 (35.7%) NS
NS — non-significant; EHRA score — EHRA classification of arrhythmia symptoms; CAD — coronary artery disease; CCB — calcium channel blocker; ACEI — angiotensin-converting enzyme inhibitor; ARB — an-
giotensin receptor blocker
Figure 1. Kaplan-Meier plot of arrhythmia-free survival; AF — atrial 
fibrillation
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paroxysmal and persistent AF who developed AAD-AFL after 
administration of amiodarone, flecainide, propafenone 
and sotalol, respectively [8]. After successful CTI abla-
tion, previously administered AAD were continued. The 
recurrence rate of AF in a mean 21-month post-ablation 
period was 33%, irrespective of the initial antiarrhythmic 
treatment. Huang et al. reported an AF recurrence rate of 
11% in an AAD-AFl population who underwent CTI ablation, 
in a 14-month follow-up [10]. More recently, Schmieder et 
al. [11] showed an observation comparing occurrence of 
AF before and after CTI ablation due to AFL. After mean 
16.3-month observation there was a significant reduction 
of AF incidence (112 patients, 33%) with reference to the 
preablation period (198 patients, 55%, p < 0.001). Anasta-
sio et al. reported AF relapse rate after such intervention 
as high as 90.3% in investigated group which completed 
a 5-year follow-up [12].
In 2014 García Seara et al. published a paper [13] that 
contained a recent analysis of a treatment of 3 populations: 
the first one including AAD-AFL patients, the second — with 
previous coexistence of AF and AFL, and the third with AFL 
alone. We should highly appreciate both the over 10-year 
follow-up period, that is rarely observed in this therapeutic 
approach, and the size of populations enrolled. Results 
have shown high incident rates, similar among AAD-AFL 
and AFL diagnosed prior to AF. Nevertheless, to our minds, 
the emphasis on following the AAD therapy was insufficient.
Multiple stressors, such as stretching of atrial myo-
cardium, episodes of AF and other supraventricular 
arrhythmias, and RAAS activation as well, may favour 
propagation of AF [14, 15]. For instance, molecular and 
histological effects of high aldosterone activity were 
evaluated in several studies. High expression of min-
eralocorticoid receptors frequently observed during AF 
caused atrial ionic remodelling [16], which was further 
attenuated by spironolactone. Animal in vivo model of 
injected aldosterone resulted in anisotropy of atrial con-
duction, recorded in a epicardial stimulation map [17]. 
Furthermore, registered conduction abnormalities were 
associated with structural remodelling represented by 
atrial fibrosis and hypertrophy, thus being responsible 
for forming a substrate for atrial arrhythmias.
Some clinical studies, including double-blind ran-
domized trials, were conducted to assess influence of 
aldosterone receptor blockers in preventing recurrences 
of AF. Spironolactone, as it was evaluated with regards 
to safety and efficacy in patients with structural heart 
diseases, seems to be an attractive alternative, or an ad-
ditional drug, for treating AF. Treatment with spironolactone 
combined with beta-adrenolytic was successful in reducing 
AF burden and the number of AF-related hospitalizations 
irrespective of structural heart disease [17, 18]. Recently 
published meta-analysis concerning RAAS blockade with 
a cumulative number of 5332 patients showed a lower risk 
of new-onset AF and recurrent AF as well. Reduction was 
even more prominent among patients without a previous 
diagnosis of heart failure [20].
Restoring and maintenance of the sinus rhythm may cut 
the vicious circle of adverse atrial remodelling caused by 
AF. Thus, our goal was to maintain the sinus rhythm in such 
population until a definitive ablation of this arrhythmia. 
Speaking of perspectives for ablation of AF in Poland, we 
must not forget about 30 procedures per million inhabitants 
per year — one of the lowest rates in the Central Europe. 
Hence, availability of PVI in Polish reference centres is still 
insufficient, with awaiting times as long as 1 year being re-
ported [21] and our clinical experience suggesting awaiting 
times up to 2–3 years in highly experienced facilities. This 
study possesses limitations as a retrospective one, due to 
relatively low number of participants and the possibility of 
hidden, asymptomatic recurrences of AF that may not have 
been detected. Therefore there is a space for long-lasting 
ECG monitoring, according to latest guidelines published 
by Baranowski et al. on behalf of Polish Cardiac Society. 
Table 2. Ablation characteristics acquired from LabSystem Pro™, reported as mean ± standard deviation
Parameter Group I 
(n = 34)
Group II 
(n = 13)
Group III 
(n = 17)
p value
Number of RF applications 21.3 ± 10.9 24.6 ± 9.9 25.5 ± 8.4 p = 0.51 
NS
Total ablation time (min) 13.7 ± 7.17 18.4 ± 8.14 16.8 ± 6.83 p = 0.37 
NS
Temperature [°C] 50.9 ± 5 50.1 ± 4.6 53.7 ± 4.9 p = 0.17 
NS
Impedance [Ω] 82.5 ± 12 82.6 ± 29 77.8 ± 10.7 p = 0.74 
NS
Power [W] 35.5 ± 15.3 35.7 ± 18.8 30.0 ± 16.8 p = 0.63 
NS
RF — radiofrequency; NS — non-significant
243www.journals.viamedica.pl/folia_cardiologica
Jakub Adamowicz et al., CTI ablation in AF
Aforementioned paper recommends to search for recur-
rences of arrhythmia in patients maintaining sinus rhythm 
after ablation [22].
Conclusions
In our study, we found that CTI ablation is a curative 
procedure for patients with typical AFL and paroxysmal 
AF with coexistent AFL. Such approach, provided that 
antiarrhythmic and spironolactone medications are used, 
is a moderately successful treatment for patients with 
persistent AF. Presented results should be confirmed in 
a prospective fashion.
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Streszczenie
Wstęp. W znacznej części populacji pacjentów z migotaniem przedsionków (AF) współistnieją napady trzepotania 
przedsionków (AFL). Zważywszy na niekorzystny efekt AF w postaci remodelingu przedsionka, istotne dla rokowania 
pacjentów jest, by okres arytmii był jak najkrótszy. W opisanym niżej badaniu, w celu uzyskania rytmu zatokowego, 
podjęto próbę leczenia ablacją prądem o częstotliwości radiowej (RF) cieśni trójdzielno-żylnej (CTI) oraz antagonistą 
receptora aldosteronowego. Celem badania była ocena wyników odległych takiego postępowania u chorych z AFL i/lub 
AF poddanych ablacji CTI.
Materiał i metody. Badana populacja składała się z 64 pacjentów (średni wiek 64,7 roku) podzielonych na 3 grupy: 
I — AFL (n = 34); II — AFL z napadami AF w wywiadzie (n = 13); III — przetrwałe AF mimo leczenia antyarytmicznego 
(n = 17). Ablację CTI przeprowadzono u wszystkich pacjentów. Pozabiegowe leczenie antyarytmiczne w grupie II rozpo-
częto u wszystkich chorych, a w grupie III kontynuowano dotychczasowe leczenie. Antagonistę receptora aldosterono-
wego zastosowano u części pacjentów z grupy I oraz u wszystkich z pozostałych grup. Okres obserwacji wynosił średnio 
13,9 miesiąca.
Wyniki. U chorych z grupy I nawrót AFL obserwowano u 3 pacjentów (8,8%), u których wykonano kolejny zabieg, po 
którym nie notowano AF/AFL podczas obserwacji. W grupie II doszło do jednego nawrotu AFL w ciągu 5 miesięcy, podda-
nego ponownej ablacji zakończonej sukcesem, oraz jednego epizodu AF (11 miesięcy bez nawrotu arytmii). W grupie III 
zanotowano 7 nawrotów AF, z następczym zabiegiem izolacji żył płucnych lub uznanych za utrwalone AF. Odsetek sku-
tecznych pierwotnych zabiegów w okresie obserwacji wyniósł 91% w porównaniu z 85% w porównaniu z 59% (p < 0,05).
Wnioski. Ablacja CTI stanowi procedurę terapeutyczną dla chorych z typowym AFL oraz osób z AFL i towarzyszącym 
napadowym AF. Zabieg ten jest umiarkowanie korzystnym rozwiązaniem u pacjentów z przetrwałym AF, pod warunkiem 
zapewnienia leczenia antyarytmicznego propafenonem i antagonistą receptora aldosteronowego. Ablacja CTI może się 
okazać terapią pomostową w przetrwałym AF przed izolacją żył płucnych służącą utrzymaniu rytmu zatokowego.
Słowa kluczowe: migotanie przedsionków, trzepotanie przedsionków, ablacja cieśni trójdzielno-żylnej, antagonista  
receptora aldosteronowego, leczenie hybrydowe
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